HFD Announces it is now a Preferred Financing Partner of Align Technology to Offer Patient Financing for Invisalign® Treatment
Dallas, Texas, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Healthcare Finance Direct (HFD), a leading provider of patient financing solutions, is thrilled to announce it is a preferred financing partner of Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry. Align US customers electing to participate will have access to HFD's innovative patient financing solutions with nearly 100% approval on patient financing applications for Invisalign treatment.
"At HFD, our mission has always been to make healthcare more affordable by providing everyone with a better way to pay," said Luke Johnson, Chief Revenue Officer of HFD. "Becoming a preferred financing partner of Align Technology is a powerful milestone towards fulfilling that mission, and we're excited to bring our virtually 100% approval financing options to their network of doctors. This will help countless patients access the orthodontic and dental care they need by alleviating the financial constraints to treatment."
"We're thrilled to make HFD our preferred patient financing partner to provide our Invisalign trained doctors with greater options to support their patients and enhance their practices," said Robert Maughn, Align Technology vice president and general manager, US. "Participating doctors can provide their patients with access to financing options that meet their needs and focus on creating new smiles that their patients will love."
Through this preferred patient financing partnership, nearly every patient financing application for Invisalign treatment will be approved. Participating doctors will also benefit from financial programs for other orthodontic and general dentistry services.
# # #
About HFD
Based in Dallas, TX, HFD is an innovative fintech platform that empowers healthcare providers to offer flexible and inclusive pay-over-time options to virtually every patient, regardless of their credit, making healthcare more accessible and affordable. Since 2009, HFD has partnered with top healthcare names to help over 1 million patients manage $2bn+ in treatment. Learn more at www.gohfd.com.
About Align Technology, Inc.
Align Technology designs and manufactures the Invisalign® system, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 271.6 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 27 years, Align has helped doctors treat over 19.5 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.
For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.
Invisalign, iTero, exocad, Align, Align Digital Platform, and iTero Lumina are trademarks of Align Technology, Inc.
CONTACT: Maggie Jackson Healthcare Finance Direct (HFD) media@gohfd.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Sabre (SABR) Stock Trades Up, Here Is Why
What Happened? Shares of travel technology company Sabre (NASDAQ:SABR) jumped 3.4% in the morning session after investment firm Bernstein upgraded the travel technology company to 'Outperform' from 'Market Perform', suggesting the market has become too pessimistic on its outlook. The upgrade comes even as Bernstein lowered its price target on the stock to $3.00 from $4.00. The move follows a significant plunge in Sabre's stock, which fell nearly 38% in a single day after a recent disappointing quarterly report that missed profit forecasts. However, Bernstein analysts believe the negative market reaction was overblown, stating the stock is now "oversold" and "too cheap." The firm argues that the market is incorrectly pricing in a structural decline for Sabre's core Global Distribution System (GDS) business. Bernstein sees a path for booking declines to stabilize and noted that the company has no major debt maturities until 2027, providing some financial stability. After the initial pop the shares cooled down to $1.92, up 1.6% from previous close. Is now the time to buy Sabre? Access our full analysis report here, it's free. What Is The Market Telling Us Sabre's shares are extremely volatile and have had 33 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was about 1 month ago when the stock dropped 4.1% on the news that the Trump administration announced intentions to impose a 35% tariff on many goods imported from Canada. This move is far more than a typical trade dispute; it targets the United States' largest and most deeply integrated trading partner. Canada is not merely a neighbor but a critical component of North American supply chains, particularly in sectors like automotive, energy, and critical minerals. This move has sparked concerns about potential retaliatory actions and a wider impact on the North American economy, leading to a risk-off sentiment among investors. The S&P 500, Dow Jones Industrial Average, and Nasdaq all opened lower, pulling back from recent record highs and heading for their first weekly loss in three weeks. Sabre is down 46.4% since the beginning of the year, and at $1.92 per share, it is trading 57.6% below its 52-week high of $4.52 from February 2025. Investors who bought $1,000 worth of Sabre's shares 5 years ago would now be looking at an investment worth $224.50. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Why Viatris (VTRS) Stock Is Up Today
What Happened? Shares of medication company Viatris (NASDAQ:VTRS) jumped 3% in the morning session after it received approval from the U.S. Food and Drug Administration (FDA) for its Iron Sucrose Injection, USP, the first generic version of Venofer® Injection. The intravenous iron replacement product is used to treat iron deficiency anemia in adult and pediatric patients with chronic kidney disease. This approval marks a significant milestone, as it's the first generic version of Venofer®, a drug with annual U.S. sales of approximately $515 million. Crucially, the U.S. Food and Drug Administration (FDA) also granted Viatris a Competitive Generic Therapy (CGT) designation for two strengths of the drug. This designation provides Viatris with 180 days of market exclusivity, giving the company a significant first-mover advantage to capture market share for this complex-to-manufacture product. After the initial pop the shares cooled down to $9.93, up 2.3% from previous close. Is now the time to buy Viatris? Access our full analysis report here, it's free. What Is The Market Telling Us Viatris's shares are not very volatile and have only had 8 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. The previous big move we wrote about was 24 days ago when the stock dropped 3.8% on the news that its experimental therapy for blepharitis, an inflammatory condition of the eyelids, failed to meet the main goal in a late-stage study. The global healthcare company announced that its Phase 3 trial for an ophthalmic ointment, pimecrolimus 0.3% (MR-139), did not achieve its primary endpoint. The study, which involved 477 patients, was designed to evaluate if the treatment led to the complete resolution of debris on the eyelids after six weeks of use. This outcome was not met, prompting the company to re-evaluate the future of the drug's development program. Viatris' Chief R&D Officer, Philippe Martin, stated that the company was considering its next steps, which could include revising an additional planned Phase 3 study for the therapy. The setback in the trial for this eye condition represents a disappointment for the company's pipeline. Viatris is down 20.1% since the beginning of the year, and at $9.93 per share, it is trading 25.8% below its 52-week high of $13.37 from November 2024. Investors who bought $1,000 worth of Viatris's shares 5 years ago would now be looking at an investment worth $596.45. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Why AAON (AAON) Shares Are Plunging Today
What Happened? Shares of heating and cooling solutions company AAON (NASDAQ:AAON) fell 15.3% in the morning session after the company reported disappointing second-quarter 2025 results that missed analyst expectations for revenue and profit, and provided a weak outlook for the upcoming quarter. The heating and cooling solutions company reported revenue of $311.6 million and adjusted earnings of $0.22 per share, falling short of Wall Street's estimates of $325 million and $0.33 per share, respectively. Furthermore, its revenue guidance for the third quarter came in 14.3% below analyst expectations, signaling continued headwinds. Profitability was a major concern, as the company's operating margin collapsed to 7.6% from 21.7% in the same quarter last year. The company also burned through $57.62 million in free cash flow, a sharp reversal from a positive figure a year ago. Overall, the combination of missed expectations, weak guidance, and sharply deteriorating profitability led to a negative reaction from investors. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy AAON? Access our full analysis report here, it's free. What Is The Market Telling Us AAON's shares are quite volatile and have had 18 moves greater than 5% over the last year. But moves this big are rare even for AAON and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 25 days ago when the stock gained 5.5% as the second quarter (2025) earnings season got off to a strong start. Quarterly earnings reports released during the week exceeded Wall Street's expectations, fueling investor confidence. Around 50 S&P 500 components reported, with 88% of those exceeding analysts' expectations, FactSet data revealed. Investors were also encouraged by several positive reports that painted a picture of a resilient consumer. One key report revealed that shoppers increased their spending at U.S. retailers more than economists had anticipated. Precisely, retail sales increased 0.6% from May, surpassing the 0.2% estimate. This robust consumer spending is a crucial pillar supporting the economy. Adding to the positive sentiment, the latest data on unemployment claims showed a decrease in the number of workers applying for benefits, signaling that layoffs remain limited and the job market is steady. This combination of strong earnings reports, retail sales, and a solid labor market suggests the economy is navigating challenges successfully. AAON is down 39.5% since the beginning of the year, and at $71.35 per share, it is trading 49.3% below its 52-week high of $140.75 from November 2024. Investors who bought $1,000 worth of AAON's shares 5 years ago would now be looking at an investment worth $1,784. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Sign in to access your portfolio
